To treating Metabolic Syndrome (MetS) in the human body by using cooked pre-germinated brown rice (PGBR), a randomized control trial was done in Vietnam. 80 subjects (65.1 ± 3.81 years old) separated into two groups in pairs were assigned a daily intake of 200 g PGBR, and the subjects in the placebo group were kept in normal living ways (consuming white rice). Before baseline and after 3 months of the intervention, anthropometric measurements, blood chemical examinations, a nutrition survey, and physical activity measurements were conducted. The main finding showed that the percentages of patients with MetS in the PGBR group were reduced significantly compared to the placebo group (p < 0.05). Serum HDL cholesterol concentrations were significantly increased from 1.11 (mmol/l) to 1.44 (mmol/l) compared to the placebo group (p < 0.05). The findings suggest that PGBR may affect HDL cholesterol, PGBR might be considered in reducing the risk of MetS in Vietnam.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109533 | PMC |
| http://dx.doi.org/10.3934/publichealth.2020005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Acupoint Application on Postoperative Sore Throat in Adults Following General Endotracheal Anesthesia: A Randomized Placebo-controlled Study.
J Perianesth Nurs
January 2025
Department of Gynecology, the First Hospital of Lanzhou University, Lanzhou, China.
Purpose: This study aims to evaluate the effect of acupoint application on the prevention of postoperative sore throat (POST), cough, expectoration, hoarseness, and patient satisfaction after general anesthesia.
Design: Randomized controlled trial.
Methods: A randomized double-blind clinical trial was designed.
Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Virol J
January 2025
Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, Guangdong, 518118, China.
Background: SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.
View Article and Find Full Text PDFContinuous serratus anterior block for sternotomy analgesia after cardiac surgery: a single-centre feasibility study.
Br J Anaesth
January 2025
Department of Anesthesia, Pain Management & Perioperative Medicine, Dalhousie University, Halifax, NS, Canada.
Background: Moderate-to-severe pain is common after cardiac surgery, peaking during the first and second postoperative days. Several nerve blocks for sternotomy have been described; however, the optimal location for continuous catheters has not been established. This study assessed the feasibility of a larger trial evaluating the efficacy of serratus anterior plane (SAP) catheter analgesia for sternotomy pain.
View Article and Find Full Text PDFSingle-centre, double-blinded, randomised placebo-controlled trial to determine the effect of a 12-week home-based programme of footplate neuromuscular electrical stimulation on walking capacity in people with peripheral artery disease: a protocol for the Foot-PAD trial.
BMJ Open
January 2025
College of Medicine and Dentistry, James Cook University, Queensland Research Centre for Peripheral Vascular Disease, Townsville, Queensland, Australia.
Introduction: Patients with peripheral artery disease (PAD) can experience intermittent claudication, which limits walking capacity and the ability to undertake daily activities. While exercise therapy is an established way to improve walking capacity in people with PAD, it is not feasible in all patients. Neuromuscular electrical stimulation (NMES) provides a way to passively induce repeated muscle contractions and has been widely used as a therapy for chronic conditions that limit functional capacity.
View Article and Find Full Text PDFPredictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial.
Gut
January 2025
Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK
Background: Low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial.
Objective: To perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA.
Design: ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!